1 Supplementary Tables and Figures

2

3 Mutational signature analyses in multi-child families suggest a key

4 role for DNA mismatch repair in human germline *de novo* mutations

5

6	Shojaeisaadi HA ¹ , Schoenrock A ^{1,#} , Meier MJ ¹ , Williams A ¹ , Norris JM ² , Palmer ND ³ ,
7	Yauk CL ⁴ , Marchetti F ^{1,*}

- 9 (1) Environmental Health Science and Research Bureau, Health Canada, Ottawa, ON, Canada
- 10 (2) Department of Epidemiology, Colorado School of Public Health, University of Colorado
- 11 Anschutz Medical Campus, Aurora, CO, USA,
- 12 (3) Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA,
- 13 (4) Department of Biology, University of Ottawa, Ottawa, Ontario, Canada.
- 14
- ¹⁵ [#]Present address: Research Computing Services, Carleton University, Ottawa, ON, Canada
- 16 * Corresponding author.
- 17 Dr. Francesco Marchetti
- 18 Environmental Health Science and Research Bureau
- 19 Health Canada
- 20 251 Sir Frederick Banting Driveway,
- 21 Ottawa, ON, K1A 0K9
- 22 Canada
- 23
- 24 Email: francesco.marchetti@hc-sc.gc.ca
- 25 Tel: +1 (613) 794-1407
- 26
- 27 Submitted to Communications Biology

IRASFS	Paternal Age (years)				
Family ID	First Child	Last Child	Difference		
1	22.7	28.6	5.9		
2	24.5	31.2	6.7		
3	24.5	38.2	13.7		
4	24.9	30.4	5.5		
5	17.5	20.2	2.7		
6	24.4	31.3	6.9		
7	16.0	21.8	5.8		
8	24.1	36.8	12.7		
9	16.4	22.3	5.9		
10	25.0	41.2	16.2		
11	26.1	40.7	14.5		
12	21.1	35.9	14.8		
13	24.7	34.0	9.3		
		Average	9.3		
First an	d last child	Median	6.9		
differ	ence (yrs)	Minimum	2.7		
		Maximum	16.2		

28	Supplementary	Table 1.	Difference in	paternal	l age at first	and last child
20		10.010 11	Difference in	pacerna		

31 **Supplementary Table 2.** Cosine similarity values of reconstructed signatures by individual

32 <u>families</u>

	<u>Mu</u>	Mutational Signatures Database			
Family	COSMIC	Germline	DNA repair KOs		
IRASFS 1	<u>0.813</u>	<u>0.656</u>	<u>0.769</u>		
IRASFS 2	<u>0.860</u>	<u>0.712</u>	<u>0.805</u>		
IRASFS 3	<u>0.904</u>	<u>0.810</u>	<u>0.805</u>		
IRASFS 4	<u>0.906</u>	<u>0.795</u>	<u>0.805</u>		
IRASFS 5	<u>0.880</u>	<u>0.811</u>	<u>0.782</u>		
IRASFS 6	0.886	<u>0.735</u>	<u>0.786</u>		
IRASFS 7	<u>0.867</u>	<u>0.769</u>	<u>0.816</u>		
IRASFS 8	<u>0.915</u>	<u>0.729</u>	<u>0.828</u>		
IRASFS 9	<u>0.878</u>	<u>0.754</u>	<u>0.766</u>		
IRASFS 10	<u>0.938</u>	<u>0.795</u>	<u>0.842</u>		
IRASFS 11	<u>0.935</u>	<u>0.830</u>	<u>0.824</u>		
IRASFS 12	<u>0.866</u>	<u>0.831</u>	<u>0.839</u>		
IRASFS 13	<u>0.954</u>	<u>0.850</u>	<u>0.853</u>		

33 Bold indicates cosine similarity values below 0.8



- 36
- Figure S1. The bioinformatic workflow. Overall bioinformatics pipeline for SNV identification, validation and subsequent parent-oforigin phasing, annotations and mutational signature analysis.



- 40 Figure S2. Process for identifying de novo single nucleotide variants (SNVs). (A) Venn diagram
- 41 showing the numbers of candidate SNVs identified by DeNovoGear and GATK. (B) Overall,
- 42 11,590 unique SNVs were identified. The 655 candidate SNVs that were identified in several
- 43 children were eliminated from further analysis generating a set of 10,955 unique candidate
- 44 SNVs. Baits were successfully designed for 6,118 (~56%) candidate SNVs. Targeted
- 45 resequencing of this set generated 2,479 SNVs that were successfully validated after applying
- 46 the necessary filtering and QC during data processing.





50 distribution of the SNVs by paternal age from a dataset from 12^{*} published trio studies with >

51 11,000 probands. The red dots show the number of validated SNVs for each of the 48 IRASFS

52 probands.

⁵³ * References: Michaelson *et al.*, Cell 2012 Dec 21;151(7):1431-42; Kong *et al.*, Nature 2012 Aug

54 23;488(7412):471-5; Dijk *et al.*, Nat Genet. 2014 Aug;46(8):818-25; Wang et al., Cell Res. 2021

55 Aug;31(8):919-928; Rahbari *et al.*, Nat Genet. 2016 Feb;48(2):126-133; Jónsson *et al.*, Nature.

56 2017 Sep 28;549(7673):519-522; Kessler et al., PNAS. 2020 Feb 4;117(5):2560-2569;

57 Halldorsson *et. al.*, Science. 2019 Jan 25;363(6425):eaau1043; Sasani et al., Elife. 2019 Sep

58 24;8:e46922; Goldman et al., Nat Genet. 2018 Apr;50(4):487-492; Goldman et al., Nat Genet.

59 2016 Aug;48(8):935-9; Wilfert *et al.*, Nat Genet. 2021 Aug;53(8):1125-1134.



62

63 Figure S4. The distribution of candindate *de novo* SNVs identified by both GATK and DenovoGear in the IRASFS multi-child

64 families and their correlation with paternal age. (A) The scatter plot represents the number of candidate *de novo* SNVs in each of

65 the 48 children by paternal age at the time of birth. Each color represents a specific IRASFS family. The blue line represents the slope

of all candidate *de novo* SNVs. (B) Scatter plots of the numbers of candidate *de novo* SNVs for each family relative to the father's age

at each child's birth, ordered by slope from the lowest (top left corner, IRASFS Family 02) to the highest rate (bottom right corner

color, IRASFS Family 05). Regression lines and 95% confidence intervals indicate the predicted number of candidate *de novo* SNVs as
a function of paternal age using a Poisson regression.



Kohailan_2022-M47 Kohailan_2022-M92 IRASFS-Family03 Kohailan_2022-M15 Kohailan_2022-M80 Kohailan_2022-M04 Sasani_2019-14 Kohailan_2022-M56 Sasani_2019-10 ₽ Sasani_2019-22 Kohailan_2022-M13 Sasani_2019-19_A Kohailan_2022-M81 Kohailan_2022-M21 Kohailan_2022-M23 Kohailan_2022-M26 Kohailan_2022-B29 Kohailan_2022-M43 Kohailan_2022-M36 Kohailan_2022-M12

73 Figure S5. Comparison of paternal age effects among multi-sibling families from diverse

- ethnic backgrounds. Slope ± 95% confidence interval (CI) of the IRASFS cohort (red) compared
- with the CEPH/Utah multi-sibling families (Sasani *et al.*, 2019; gray) and Middle-East multiplex
- families (Kohailan *et al.*, 2022; green). Each family is sorted in order of increasing slope. Dashed
- vertical lines indicate the combined paternal age effect based on all families within a study,
- 78 with colours representing the corresponding cohorts: 1.29 de novo SNVs/year, 95% CI: 1.44-
- 79 1.57, p < 0.0001 for IRASFS (red); 1.72 de novo SNVs/year, 95% CI: 1.58–1.85, p < 2e-16 for the
- 80 CEPH/Utah (grey); and, 1.36 de novo SNVs/year, 95% CI: 1.11–1.61, p = 1 × 10[^]–22 for Middle-
- 81 East multiplex families cohort (green).